X4 Pharmaceuticals, Inc reports material agreement in SEC 8-K

X4 Pharmaceuticals, Inc filed an 8-K covering a material definitive agreement, termination of a material definitive agreement, a direct financial obligation, and an unregistered sale of equity securities. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.